Evidence map›Paper›PMID 38328518›Full record

ArticleFrontiers in psychiatry2023

Adapting the ADVANCE group program for digitally-supported delivery to reduce intimate partner violence by men in substance use treatment: a feasibility study.

Gail Gilchrist, Sandi Dheensa, Amy Johnson, Juliet Henderson, Polly Radcliffe, Georges Dwyer, Richard Turner, Kate Thomson, Cat Papastavrou Brooks, Beverly Love and 9 more

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gail Gilchrist *National Addiction Center, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Sandi DheensaPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Amy JohnsonSchool of Health in Social Science, Department of Clinical Psychology, Center for Psychological Therapies, University of Edinburgh, Edinburgh, United Kingdom.
Juliet HendersonNational Addiction Center, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Polly RadcliffeNational Addiction Center, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Georges DwyerNational Addiction Center, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Richard TurnerNational Addiction Center, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Kate ThomsonSchool of Health in Social Science, Department of Clinical Psychology, Center for Psychological Therapies, University of Edinburgh, Edinburgh, United Kingdom.
Cat Papastavrou BrooksPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Beverly LoveNational Addiction Center, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Zohra ZenasniDepartment of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Cassandra BerbaryCollege of Health Sciences and Technology, Rochester Institute of Technology, Rochester, NY, United States.
Ben CarterNational Addiction Center, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
Steve ParrottDepartment of Health Sciences, University of York, York, United Kingdom.
Jinshuo LiDepartment of Health Sciences, University of York, York, United Kingdom.
Caroline EastonCollege of Health Sciences and Technology, Rochester Institute of Technology, Rochester, NY, United States.
Ciara BergmanRespect, London, United Kingdom.
Gene FederPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Elizabeth Gilchrist *School of Health in Social Science, Department of Clinical Psychology, Center for Psychological Therapies, University of Edinburgh, Edinburgh, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: COVID-19 restrictions created barriers to "business as usual" in healthcare but also opened the door to innovation driven by necessity. This manuscript (1) describes how ADVANCE, an in-person group perpetrator program to reduce intimate partner violence (IPV) against female (ex)partners by men in substance use treatment, was adapted for digitally-supported delivery (ADVANCE-D), and (2) explores the feasibility and acceptability of delivering ADVANCE-D to men receiving substance use treatment. Methods: Firstly, the person-based approach and mHealth development framework were used to iteratively adapt ADVANCE for digitally-supported delivery including conceptualization, formative research, and pre-testing. Then, a non-randomized feasibility study was conducted to assess male participants' eligibility, recruitment, and attendance rates and uptake of support offered to their (ex)partners. Exploratory analyses on reductions in IPV perpetration (assessed using the Abusive Behavior Inventory; ABI) and victimization (using the revised ABI; ABI-R) at the end of the program were performed. Longitudinal qualitative interviews with participants, their (ex)partners, and staff provided an understanding of the program's implementation, acceptability, and outcomes. Results: The adapted ADVANCE-D program includes one goal-setting session, seven online groups, 12 self-directed website sessions, and 12 coaching calls. ADVANCE-D includes enhanced risk management and support for (ex)partners. Forty-five participants who had perpetrated IPV in the past 12 months were recruited, forty of whom were offered ADVANCE-D, attending 11.4 (SD 9.1) sessions on average. Twenty-one (ex)partners were recruited, 13 of whom accepted specialist support. Reductions in some IPV perpetration and victimization outcome measures were reported by the 25 participants and 11 (ex)partners interviewed pre and post-program, respectively. Twenty-two participants, 11 (ex)partners, 12 facilitators, and 7 integrated support service workers were interviewed at least once about their experiences of participation. Overall, the program content was well-received. Some participants and facilitators believed digital sessions offered increased accessibility. Conclusion: The digitally-supported delivery of ADVANCE-D was feasible and acceptable. Remote delivery has applicability post-pandemic, providing greater flexibility and access. Given the small sample size and study design, we do not know if reductions in IPV were due to ADVANCE-D, time, participant factors, or chance. More research is needed before conclusions can be made about the efficacy of ADVANCE-D.

Indexed as

ADVANCE-Dblended interventionsdigital interventionsintegrated interventionintimate partner violenceperpetratorremote deliverysubstance use treatment

Identifiers

PMID38328518
PMCPMC10847362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.